Archives of Osteoporosis最新文献

{"title":"Opportunistic computed tomography (CT) assessment of osteoporosis in patients undergoing transcatheter aortic valve replacement (TAVR).","authors":"Michael Paukovitsch, Tom Fechner, Dominik Felbel, Johannes Moerike, Wolfgang Rottbauer, Steffen Klömpken, Horst Brunner, Christopher Kloth, Meinrad Beer, Anjany Sekuboyina, Dominik Buckert, Jan S Kirschke, Nico Sollmann","doi":"10.1007/s11657-025-01579-4","DOIUrl":"10.1007/s11657-025-01579-4","url":null,"abstract":"<p><p>CT-based opportunistic screening using artificial intelligence finds a high prevalence (43%) of osteoporosis in CT scans obtained for planning of transcatheter aortic valve replacement. Thus, opportunistic screening may be a cost-effective way to assess osteoporosis in high-risk populations.</p><p><strong>Background: </strong>Osteoporosis is an underdiagnosed condition associated with fractures and frailty, but may be detected in routine computed tomography (CT) scans.</p><p><strong>Methods: </strong>Volumetric bone mineral density (vBMD) was measured in clinical routine thoraco-abdominal CT scans of 207 patients for planning of transcatheter aortic valve replacement (TAVR) using an artificial intelligence (AI)-based algorithm.</p><p><strong>Results: </strong>43% of patients had osteoporosis (vBMD < 80 mg/cm³ L1-L3) and were elderly (83.0 {interquartile range [IQR]: 78.0-85.5} vs. 79.0 {IQR: 71.8-84.0} years, p < 0.001), more often female (55.1 vs. 28.8%, p < 0.001), and had a higher Society of Thoracic Surgeon's score for mortality (3.0 {IQR:1.8-4.6} vs. 2.1 {IQR: 1.4-3.2}%, p < 0.001). In addition to lumbar vBMD (58.2 ± 14.7 vs. 106 ± 21.4 mg/cm³, p < 0.001), thoracic vBMD (79.5 ± 17.9 vs. 127.4 ± 26.0 mg/cm³, p < 0.001) was also significantly reduced in these patients and showed high diagnostic accuracy for osteoporosis assessment (area under curve: 0.96, p < 0.001). Osteoporotic patients were significantly more often at risk for falls (40.4 vs. 22.9%, p = 0.007) and required help in activities of daily life (ADL) more frequently (48.3 vs. 33.1%, p = 0.026), while direct-to-home discharges were fewer (88.8 vs. 96.6%, p = 0.026). In-hospital bleeding complications (3.4 vs. 5.1%), stroke (1.1 vs. 2.5%), and death (1.1 vs. 0.8%) were equally low, while in-hospital device success was equally high (94.4 vs. 94.9%, p > 0.05 for all comparisons). However, one-year probability of survival was significantly lower (84.0 vs. 98.2%, log-rank p < 0.01).</p><p><strong>Conclusion: </strong>Applying an AI-based algorithm to TAVR planning CT scans can reveal a high rate of 43% patients having osteoporosis. Osteoporosis may represent a marker related to frailty and worsened outcome in TAVR patients.</p>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"100"},"PeriodicalIF":3.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data from a national survey on management of CKD-associated osteoporosis among Italian nephrologists.","authors":"Maria Fusaro, Althea Cossettini, Giulia Vanessa Re Sartò, Andrea Aghi, Maria Cristina Mereu, Maurizio Gallieni, Laura Cosmai, Antonio Bellasi, Carlo Maria Alfieri, Daniel Cejka, Eugene McCloskey, Etienne Cavalier, Nicholas C Harvey, Thomas L Nickolas, Maria Luisa Brandi, Serge Ferrari, Carmela Marino, Sandro Giannini, Stefania Sella, Gaetano Paride Arcidiacono, Paolo Simioni, Mario Plebani, Martina Zaninotto, Luca De Nicola, Carmelita Marcantoni, Martin H de Borst, Maura Ravera, Bruno Frediani, Jordi Bover, Marie-Helene Lafage-Proust, Jean-Yves Reginster, Francesco Bertoldo, Giovanni Tripepi, Mathias Haarhaus","doi":"10.1007/s11657-025-01570-z","DOIUrl":"https://doi.org/10.1007/s11657-025-01570-z","url":null,"abstract":"<p><p>Chronic kidney disease (CKD)-associated osteoporosis increases fracture risk, yet clinical guidance remains unclear. A survey of 89 Italian nephrologists revealed heterogeneous biomarker availability and varied treatment approaches. Denosumab was the preferred antiresorptive agent, while anabolic drugs were rarely used. Findings highlight progress in CKD-related bone health management despite existing uncertainties. CKD-associated osteoporosis comprises the skeletal effects of a complex mineral and bone disorder causing increased risks of fragility fractures (FF), cardiovascular events, and mortality. Existing clinical guidance about CKD-associated osteoporosis is vague, leading us to hypothesize that a treatment gap exists and that clinical practice is dependent on local availability of diagnostic tools.</p><p><strong>Purpose and methods: </strong>The aim of the current survey was to determine current attitudes and practices among Italian nephrologists regarding the evaluation and management of CKD-associated osteoporosis. An online survey was designed, consisting of 9 thematic groups with a set of 16 closed questions regarding the availability of biomarkers and BTMs at reference laboratories and their use for the diagnosis and treatment of CKD-associated osteoporosis in patients with different stages of CKD, including CKD stages G4-5 and dialysis patients. Results were compared to a previous survey on the use of BTMs from 2022.</p><p><strong>Results: </strong>Eighty-nine Italian nephrologists participated in the survey, reporting that parathyroid hormone (PTH), alkaline phosphatase, and 25-hydroxy-vitamin D measurements were available in 92-100% of their reference laboratories. Measurements for fibroblast growth factor-23, Klotho, Matrix Gla protein, procollagen type 1 N-terminal propeptide, and tartrate-resistant acid phosphatase 5b were available in 64-74% of cases. Regarding PTH cut-off values, 47.2% followed KDOQI and 43.8% followed KDIGO recommendations. Vitamin D was widely used across CKD stages (cholecalciferol 27-37.1%, calcifediol 9-12.4%, calcitriol 47.2-53.9%, and paricalcitol 21.3-30.3). Denosumab was the preferred antiresorptive agent in all CKD stages (22.5%-28.1%), while the use of bisphosphonates was uncommon in advanced CKD. Anabolic drugs were rarely prescribed.</p><p><strong>Conclusions: </strong>The availability of bone biomarkers is heterogeneous, and an uncertainty still exists regarding the clinical use of biomarkers in CKD-associated osteoporosis. Nonetheless, our findings indicate that Italian nephrologists are increasingly taking proactive steps to prevent and treat bone fragility in CKD patients.</p>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"96"},"PeriodicalIF":3.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival and probability of death due to fragility hip fracture in patients over 65 years of age: a retrospective cohort study.","authors":"Maria Dolors Rosinés, Mercè Castejón, Joan Espaulella-Panicot, Anna Arnau","doi":"10.1007/s11657-025-01585-6","DOIUrl":"https://doi.org/10.1007/s11657-025-01585-6","url":null,"abstract":"<p><p>Fragility hip fractures significantly impact long-term survival in patients over 65 years. Overall survival was 76.0% (95% CI 74.4-77.7), 37.7% (95% CI 35.6-39.9), and 11.9% (95% CI 9.6-14.8) at 1, 5, and 10 years. Advanced age, male sex, and cognitive/functional impairment increased mortality. Comprehensive assessments are essential for personalized treatment.</p><p><strong>Purpose: </strong>Fragility hip fractures are increasing due to population aging. The main objective of this study was to determine long-term survival and the probability of dying from hip fracture or from other causes in patients over 65 years old who underwent surgery for a fragility hip fracture.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted between June 2010 and December 2021. The main outcomes were overall survival, relative survival, and the probability of dying either from hip fracture or from other causes at 1, 5, and 10 years after surgery determined with the WebSurvCa application.</p><p><strong>Results: </strong>A total of 2646 patients were included with a median age of 86.3 years [81.7-90.3]; 75% were women. Overall survival was 76.0% (95% CI 74.4-77.7), 37.7% (95% CI 35.6-39.9), and 11.9% (95% CI 9.6-14.8) at 1, 5, and 10 years. The cumulative probability of dying from a hip fracture was 17.2%, 35.4%, and 49.4% at 1, 5, and 10 years, respectively. Factors such as advanced age, male sex, and prior functional or cognitive deterioration were associated with worse long-term survival. In patients over 85 years old, without functional dependence or with normal cognitive status, the probability of dying from other causes at 5 and 10 years exceeded that of dying from the hip fracture.</p><p><strong>Conclusion: </strong>Our results highlight that long-term mortality in these patients is high, persisting even 10 years after the fracture. Comprehensive evaluation considering age, functional, and cognitive status is essential in order to predict outcomes and personalize treatment strategies.</p>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"99"},"PeriodicalIF":3.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporosis treatment gap after hip fracture: data from a tertiary center in Turkey.","authors":"Sezin Doğan Çakır, Mustafa Yerli, Mesut Sonmez, Mine Adas","doi":"10.1007/s11657-025-01584-7","DOIUrl":"https://doi.org/10.1007/s11657-025-01584-7","url":null,"abstract":"<p><p>This study investigates the osteoporosis treatment gap and mortality following hip fractures in Turkey. We found that 83.1% of patients did not receive post-fracture osteoporosis treatment, with a 1-year mortality rate of 37%. Prior treatment, younger age, and parenteral medications were significant predictors of treatment adherence. These findings highlight the urgent need to address treatment gaps and improve patient outcomes.</p><p><strong>Objective: </strong>This study aimed to evaluate the osteoporosis treatment gap, mortality rates, and predictors of mortality in hip fracture patients in a tertiary center in Turkey.</p><p><strong>Methods: </strong>A retrospective analysis was conducted of 552 patients aged over 50 years who were hospitalized for hip fractures at Prof. Dr. Cemil Taşcıoglu City Hospital between January 2015 and November 2022. Data were collected from electronic medical records, including pre- and post-fracture osteoporosis treatment, treatment initiation times, bone mineral density (BMD) tests, and patient outcomes.</p><p><strong>Results: </strong>The mean age of the cohort was 80.2 years, with a predominance of female patients (65.1%). Prior to the fracture, 90.8% of patients had not received osteoporosis treatment. After the fracture, 83.1% of patients did not receive any osteoporosis medications. Of those treated, 45 patients (8.6%) started treatment within 3 months. The 1-year mortality rate was 37%, with significant predictors including age, male gender, lack of prior osteoporosis treatment, delayed treatment initiation, and short treatment duration. Only 5.6% of patients had a BMD test within the first year after the fracture, which was associated with improved treatment adherence and lower mortality.</p><p><strong>Conclusions: </strong>The study highlights a significant treatment gap for osteoporosis in hip fracture patients in Turkey. Prior treatment history, younger age, and use of parenteral therapies were strong predictors of adherence to post-fracture osteoporosis treatment. These findings emphasize the need for improved healthcare provider awareness, better treatment initiation protocols, and the implementation of Fracture Liaison Services.</p>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"97"},"PeriodicalIF":3.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between type 2 diabetes mellitus, prediabetes, and bone mineral density in middle-aged and older adults: a nationwide study.","authors":"Cheng-Yen Liao, Ai-Ru Hsieh, Ya-Min He, Hua-Chun Chen, Chung-Lan Kao","doi":"10.1007/s11657-025-01580-x","DOIUrl":"https://doi.org/10.1007/s11657-025-01580-x","url":null,"abstract":"<p><p>This retrospective analysis of 11,595 individuals aged ≥ 50 years from the Taiwan Biobank demonstrated that prediabetes and type 2 diabetes mellitus (T2DM) were associated with higher bone mineral density (BMD). Prolonged T2DM duration correlated with increased lumbar spine BMD, while its effect on femoral neck BMD was nonsignificant after adjusting for confounding factors.</p><p><strong>Purpose: </strong>The relationship between T2DM, prediabetes and BMD has remained uncertain due to conflicting findings in previous research. This study aims to investigate the association between T2DM, prediabetes and BMD among middle-aged and older adults with Taiwan Biobank database.</p><p><strong>Methods: </strong>The retrospective study included 11,595 patients aged ≥ 50 years from the Taiwan Biobank (2012-2021), comprising 2,476 in the control group, 6,877 in the prediabetes group, and 2,242 in the T2DM group. Categorical variables were analyzed with Pearson's chi-square, and continuous data was obtained using the Mann-Whitney U test. Significant variables (p < 0.05) in the univariate analysis were included in a multivariate logistic regression analysis. Patients with T2DM or prediabetes exhibited higher BMD at all measured sites compared to controls (p < 0.001).</p><p><strong>Results: </strong>Multivariable analysis demonstrated that both conditions were independently associated with a lower osteoporosis rate. Individuals with T2DM for > 10 years had higher lumbar spine BMD compared to those with T2DM for 5-10 or < 5 years. However, T2DM duration > 10 years was associated with lower BMD at the bilateral femoral necks compared to those with a duration of 5-10 years. After adjusting for confounders, diabetes duration ≥ 10 years was no longer a significant predictor of lower femoral neck BMD. In the normal-weight category, individuals with T2DM had a significantly lower prevalence of osteoporosis than those with prediabetes and controls (p < 0.001). This inverse association was not observed in the underweight, overweight, or obese groups.</p><p><strong>Conclusions: </strong>Prediabetes and T2DM are correlated with higher BMD in middle-aged and older adults. A longer T2DM duration is associated with increased BMD at the lumbar spine but not the femoral neck after adjusting for confounders.</p>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"98"},"PeriodicalIF":3.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Exploring the shared genetic architecture of type 2 diabetes mellitus and bone mineral density.","authors":"Xinran Feng, Hongbin Xu, Qian Guo, Zeying Wang, Ruikai Ba, Kun Xuan, Jinghao Ban","doi":"10.1007/s11657-025-01581-w","DOIUrl":"https://doi.org/10.1007/s11657-025-01581-w","url":null,"abstract":"","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"94"},"PeriodicalIF":3.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Acquired hypophosphatemic osteomalacia: case series from a Peruvian referral center (1999-2023).","authors":"José Paz-Ibarra, Sofía Sáenz-Bustamante, Manuel Inostroza-Fernández, Paola Sifuentes Hermenegildo, Liliana Ancajima Lescano, Marcio Concepción-Zavaleta, Alejandro Román-González, Alfredo Adolfo Reza-Albarrán","doi":"10.1007/s11657-025-01583-8","DOIUrl":"https://doi.org/10.1007/s11657-025-01583-8","url":null,"abstract":"","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"92"},"PeriodicalIF":3.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of denosumab and zoledronic acid discontinuation in hip fracture surgery: a nationwide database study.","authors":"Seok Ha Hong, Yeon Ju Yu, Seung Beom Han","doi":"10.1007/s11657-025-01560-1","DOIUrl":"https://doi.org/10.1007/s11657-025-01560-1","url":null,"abstract":"<p><p>In hip fracture patients with poor medication adherence, DMAB discontinuation significantly increased the risk of subsequent vertebral and rib fractures. Additionally, higher CCI scores were associated with an increased risk of these fractures. These findings underscore the importance of maintaining treatment adherence to minimize fracture risk in this vulnerable population.</p><p><strong>Purpose: </strong>To assess the risk of major osteoporotic fractures and periprosthetic fractures in hip fracture patients who discontinued denosumab (DMAB) or zoledronic acid (ZOL).</p><p><strong>Methods: </strong>Data from the South Korean National Health Insurance Review and Assessment Service were analyzed, focusing on patients aged ≥ 60 years who underwent hip fracture surgery and initiated DMAB or ZOL treatment. Among 20,180 patients, 1737 discontinued DMAB, and 3720 discontinued ZOL. After 1:1 propensity score matching, 3240 patients were included in the final analysis. The DMAB group was stratified into three subgroups based on the cumulative DMAB duration after hip fracture surgery: 1-2, 2-3, and > 3 Y. Discontinuation was defined as a 270-day gap for DMAB or 540-day gap for ZOL last injections. Subsequent osteoporotic fractures after discontinuation were evaluated.</p><p><strong>Results: </strong>DMAB discontinuation significantly increased the risk of subsequent vertebral fractures (hazard ratio [HR] = 1.81; 95% confidence interval [CI], 1.28-2.56, P = 0.01) and rib fractures (HR = 2.04; 95% CI, 1.27-3.23, P = 0.004) compared to ZOL discontinuation. Higher Charlson Comorbidity Index (CCI) scores were also significantly associated with an increased risk of subsequent vertebral (HR 1.05, 95% CI 1.03-1.09, P = 0.02) and rib fractures (HR 1.12, 95% CI 1.06-1.19, P < 0.01). Although the incidence of hip fractures was lower in DMAB discontinuation group (1 case) than in the ZOL discontinuation group (10 cases), this difference did not reach statistical significance. No significant difference was observed in the risk of other nonvertebral fractures (humerus, wrist, ankle) and periprosthetic fracture between the two groups.</p><p><strong>Conclusion: </strong>This nationwide study, the first to use real-world data, highlighted the significant increase in the risk of vertebral and rib fracture associated with DMAB discontinuation in patients with poor adherence and higher comorbidity burden. Optimizing medication adherence is crucial to minimize the fracture risk in this vulnerable population.</p><p><strong>Level of evidence: </strong>Level III, Prognostic.</p>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"93"},"PeriodicalIF":3.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144635981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between ramelteon use and risk of fragility fractures: A retrospective cohort study.","authors":"Hitoshi Tange, Yoshihisa Miyamoto, Yusuke Sasabuchi, Hideo Yasunaga","doi":"10.1007/s11657-025-01582-9","DOIUrl":"https://doi.org/10.1007/s11657-025-01582-9","url":null,"abstract":"<p><p>The effect of melatonin receptor agonists on bone remains unclear. This retrospective cohort study provides the first evidence that the short- to mid-term use of ramelteon is not associated with the risk of fracture. Further research with longer follow-up is needed to clarify the effects of ramelteon on bone health.</p><p><strong>Background: </strong>Recent studies have suggested that melatonin may have the potential to treat osteoporosis. However, few studies have examined the effects of melatonin receptor agonists on bone health. This study aimed to evaluate the association between ramelteon use and the risk of fragility fractures.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study from April 2014 to November 2022 using the DeSC database, a large healthcare claims database in Japan, employing an active comparator and new-user design. Female participants aged ≥ 50 years were included in the study. Exposure was defined as the first dispensation of ramelteon or orexin receptor antagonists. The outcome was a composite of major fragility fractures, including hip, vertebral, wrist, proximal humeral, and ankle fractures. To adjust for potential confounders, we used overlap weighting analysis with propensity scores. Cox regression analyses were performed both before and after applying overlap weighting.</p><p><strong>Results: </strong>A total of 106,511 individuals were identified, including 23,312 new ramelteon users and 83,199 new orexin receptor antagonist users. The overall fracture incidence was 9,429 per 100,000 person-years in the ramelteon group and 7,330 per 100,000 person-years in the orexin receptor antagonist group. The adjusted hazard ratio for overall fractures associated with ramelteon use was 1.07 (95% confidence interval: 0.99-1.17). The results were consistent across fracture types, age groups, and landmark analyses.</p><p><strong>Conclusions: </strong>In a real-world setting, short- to mid-term ramelteon use was not associated with an increased risk of fractures. Future studies should consider longer follow-up periods to further investigate the effects of ramelteon on bone health.</p>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"95"},"PeriodicalIF":3.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of gestational age and intrauterine growth on bone mass in adolescents: findings from a Brazilian Birth Cohort Study.","authors":"Isabel Oliveira Bierhals, Luciana Tovo-Rodrigues, Alicia Matijasevich, Iná S Santos","doi":"10.1007/s11657-025-01574-9","DOIUrl":"https://doi.org/10.1007/s11657-025-01574-9","url":null,"abstract":"<p><p>Osteoporosis in adulthood often originates in early life, and some forms can be prevented through appropriate attention to bone health during the neonatal period and childhood, particularly in cases involving preterm infants or with intrauterine growth restriction.</p><p><strong>Purpose: </strong>To test the association of gestational age and intrauterine growth with bone mass in adolescents.</p><p><strong>Methods: </strong>With data from the 2004 Pelotas Birth Cohort, the outcomes density (aBMD) and content (BMC) were obtained by dual-energy X-ray absorptiometry, measured at 15 years. The exposures of interest were: prematurity (< 37 weeks of gestation), gestational age (≤ 36, 37-41, and ≥ 42 weeks) and intrauterine growth (small - SGA, appropriate - AGA or large for gestational age - LGA). Linear regression stratified by sex was run. Exclusive breastfeeding at 3 months was tested as an effect modifier.</p><p><strong>Results: </strong>One thousand four hundred ninety-four participants were included. In full adjusted model, including adolescent's height, preterm females had lower aBMD femoral neck than the full-term (β - 0.04 g/cm²; 95% CI - 0.07; - 0.01; p = 0.012) and those born with ≥ 42 weeks of gestation (β - 0.07 g/cm²; 95% CI - 0.13; - 0.01; p = 0.026). Males born with ≤ 36 and 37-41 weeks of gestation presented less BMC femoral neck than those born with ≥ 42 weeks (β - 0.8 g; 95% CI - 1.4; - 0.2 and β - 0.8 g; 95% CI - 1.4; - 0.2, respectively). LGA females presented approximately 100 g more in the whole-body BMC (β 97.3 g; 95% CI 20.5; 174.1; p = 0.022) than AGA females. SGA females who received exclusive breastfeeding at 3 months presented higher BMD (lumbar spine and femoral neck) and BMC than those who did not receive exclusive breastfeeding.</p><p><strong>Conclusion: </strong>Even the adolescence phase can be impaired due to premature birth and intrauterine growth restriction.</p>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":"89"},"PeriodicalIF":3.1,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}